Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST316 in Advanced Solid Tumors
NCT05848739Phase 1Active, not recruiting
- Sponsor
- Sapience Therapeutics, Inc.
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ST316 in solid tumor, colorectal cancer (CRC), hepatocellular carcinoma (HCC) and 6 more (5 arms), sponsored by Sapience Therapeutics, Inc. Primary endpoint: Treatment-Related Adverse Events at 3 years. Started Jun 2023; status: active, not recruiting.
02
Drugs
ST316
03
Conditions
solid tumorcolorectal cancer (CRC)hepatocellular carcinoma (HCC)triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05848739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05848739.